2026-02-17
NextCell Participating in JETRO’s Japan Entry Acceleration Program
NextCell Pharma AB (“NextCell” or the “Company”) announces its participation in the Japan Entry Acceleration Program (“JEAP”) in regenerative medicine, an international accelerator initiative organized and funded by JETRO. NextCell is communicating its participation in connection with the Company’s current presence in Tokyo, where program activities and meetings with Japanese industrial, regulatory and financial stakeholders are now taking place.
Read moreRead more2026-02-03
Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes
NextCell Pharma AB (“NextCell” or the “Company”) today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with newly diagnosed type 1 diabetes. The data extends to approximately 6 years after the last ProTrans infusion, corresponding to 7 to 7.5 years since the first infusion.
Read moreRead more2026-01-21
NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market
NextCell Pharma AB (“NextCell” or the “Company”) provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans™ in adult patients, where NextCell already has a strong clinical foundation, while simultaneously strengthening the company’s global partnering position. This approach builds on NextCell’s original development strategy and is designed to create multiple independent value drivers for the company.
Read moreRead more2026-01-21
NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL)
The shareholders of NextCell Pharma AB (publ), reg. no. 556965-8361, (the "Company") are hereby invited to attend an extraordinary general meeting on Tuesday, 10th of February 2026, at 10:00 CET at Novum-huset, floor 6 (lift E), Hälsovägen 7, Huddinge. Registration for the meeting will commence at 09.30 CET.
Read moreRead more2026-01-21
NextCell decides to propose a directed share issue of SEK 15 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.
The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has resolved to propose to the extraordinary general meeting (the “Extraordinary General Meeting”) to resolve on a directed share issue comprising a total of 15,000,000 shares to a number of strategic investors at a subscription price of SEK 1.00 per share (the “Directed Issue”). Participating investors include both new investors and a number of larger existing shareholders. The Extraordinary General Meeting is planned to be held on Tuesday, 10 February 2026. Notice of the Extraordinary General Meeting will be announced separately.
Read moreRead more2026-01-15
Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes
NextCell Pharma AB (“NextCell” or the “Company”) today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation of endogenous insulin production in patients with newly-diagnosed type 1 diabetes. Patients treated with ProTrans continue to exhibit clinically relevant levels of stimulated C-peptide well beyond expected levels as seen with the natural course of the disease.
Read moreRead more2025-12-09
NextCell in Swedish Life Science Delegation to Hong Kong
NextCell Pharma AB (“NextCell” or “the Company”) is participating in the Swedish life science delegation to Hong Kong on 10–12 December 2025, organised by the Hong Kong Chamber of Commerce in Sweden and the Hong Kong Biotechnology Organisation (HKBIO). The delegation brings together leading Swedish companies to deepen collaborations in research, clinical development, industrial production, and investment in Hong Kong and the Greater Bay Area (GBA).
Read moreRead more2025-12-02
NextCell initiates collaboration with OptiCell – strengthening its cell-handling operations
NextCell Pharma AB (“NextCell” or “the Company”) has entered into a collaboration agreement with OptiCell Solutions AB (“OptiCell”) regarding the handling, freezing, storage, and transport of cell products used for research and development. The collaboration enables NextCell to further leverage its existing infrastructure and expertise in advanced cell handling, also beyond its own clinical projects.
Read moreRead more